Research programme: Autoimmune disorders gene therapy - Lapix Therapeutics
Latest Information Update: 29 Jun 2023
At a glance
- Originator LAPIX Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immune checkpoint protein stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 11 Apr 2023 Lapix Therapeutics plans early POB study for Autoimmune disorders
- 09 Apr 2023 Early research in Autoimmune disorders in USA (Parenteral) (Lapix Therapeutics Pipeline, April 2023)